MedDataX Logo

Post-Filter Hematocrit

NCT ID: NCT07293936

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-15

Study Completion Date

2026-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Filter clotting is a major complication of continuous renal replacement therapy (CRRT), resulting in blood loss, reduced treatment efficacy, and increased cost. One modifiable factor associated with filter clotting is filtration fraction (FF), or the proportion of plasma water being removed from the blood over the course of the filter. In convention, a cutoff of FF\<20-30% has been used to prevent hemofilter clotting, but no evidence correlating FF with hemofilter clotting has been documented. Some experts have proposed that post-filter hematocrit (Hct) could be a more direct marker for determining hemofilter clotting risk, but evidence supporting clinical utility of this marker is lacking.

HCTpost=HCTpre/(FF(HCTpre-1)+1)

In our proposed validation study, we hope to determine whether our formula for post-filter Hct provides accurate results when compared to measured values. The information obtained from this study will potentially justify the use of utilizing the formula in future studies.

The procedure of this study is collecting blood samples from the post-filter lines of patients on CRRT at different time points and different flow rates. This will be considered the "measured post-filter hematocrit" which will then be compared to the calculated formula above, using the other values obtained from daily labs (for pre-filter hematocrit) and CRRT machine settings.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This investigational study is listed as "other" because it is a validation study comparing two measurement methods-comparing a calculated versus a machine-measured post-filter hematocrit- and is typically classified as a cross-sectional investigational study in the context of diagnostic or method comparison research.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Continuous Renal Replacement Therapy Renal Failure Hemofilter Clotting

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

crrt continuous renal replacement therapy hemofilter clotting post-filter hematocrit filtration fraction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

All participants will undergo the same "intervention" of both using their blood samples to measure post-filter hematocrit and using their other lab values and CRRT settings to calculate post-filter hematocrit.
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CRRT patients

All participants will receive the same "intervention" of both measuring and calculating post-filter hematocrit.

Group Type OTHER

Calculated Post-Filter Hematocrit

Intervention Type OTHER

using the formula: HCTpost=HCTpre/(FF(HCTpre-1)+1)

Measured Post-Filter Hematocrit

Intervention Type OTHER

Measured from blood sample taken from CRRT machine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Calculated Post-Filter Hematocrit

using the formula: HCTpost=HCTpre/(FF(HCTpre-1)+1)

Intervention Type OTHER

Measured Post-Filter Hematocrit

Measured from blood sample taken from CRRT machine

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients initiated on CRRT age equal than or greater to 18 years of age

Exclusion Criteria

* patients on ECMO
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gwyndolyn M. Radford

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gwyndolyn M. Radford

Principal Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gwyndolyn M Radford, MD

Role: CONTACT

Phone: 7858179620

Email: [email protected]

Benjamin R Griffin, MD

Role: CONTACT

Phone: 5073631404

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gwyndolyn M Radford, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

202412294

Identifier Type: -

Identifier Source: org_study_id